Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

BS_G63HYD6N

Supratentorial Ependymoma

985f01ab-f9c1-56cb-a001-4a888ef35831

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Supratentorial Ependymoma
cancer_type_detailed
—
subtype
—
cancer_type
Supratentorial Ependymoma
overall_survival_months
69.80946123521682
age_years
11.378
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.369
  • OXIDATIVE_PHOSPHORYLATION+0.362
  • UNFOLDED_PROTEIN_RESPONSE+0.354
  • PROTEIN_SECRETION+0.353
  • DNA_REPAIR+0.351
  • PANCREAS_BETA_CELLS+0.272
  • WNT_BETA_CATENIN_SIGNALING+0.272
  • UV_RESPONSE_UP+0.222
  • PI3K_AKT_MTOR_SIGNALING+0.216
  • ADIPOGENESIS+0.204

Top 10 suppressed

  • IL6_JAK_STAT3_SIGNALING-0.459
  • KRAS_SIGNALING_UP-0.407
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.395
  • ALLOGRAFT_REJECTION-0.384
  • COMPLEMENT-0.378
  • INFLAMMATORY_RESPONSE-0.362
  • TNFA_SIGNALING_VIA_NFKB-0.341
  • COAGULATION-0.321
  • IL2_STAT5_SIGNALING-0.304
  • APICAL_SURFACE-0.265

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_G63HYD6N
medullo-epn-umap@date-based
EPNSupratentorial EPN0.938
2BS_7G42J2SK
brain-umap@2
Supratentorial Ependymoma—0.852
3BS_FTKPQ5FZ
brain-umap@2
Supratentorial Ependymoma—0.845
4BS_H4NXBD2D
brain-umap@2
Supratentorial Ependymoma—0.840
5BS_QXKRN6CR
brain-umap@2
Supratentorial Ependymoma—0.839
6BS_TJTEF70D
brain-umap@2
high-grade glioma—0.834
7TCGA-DK-A3IS-01A-21R-A21D-07
bladder-landscape@3
——0.832
8BS_QXKRN6CR
medullo-epn-umap@date-based
EPNSupratentorial EPN0.817
9004064de-0e10-491d-b3d8-bc628a8f70a8
melanoma-umap@29
——0.812
10SRR12202462
bladder-landscape@3
——0.812

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.369Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.362Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.354Idelalisib— uncovered
PROTEIN_SECRETION0.353Remibrutinib— uncovered
DNA_REPAIR0.351Idelalisib— uncovered
PANCREAS_BETA_CELLS0.272Cobimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.272Inavolisib— uncovered
UV_RESPONSE_UP0.222Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.216Inavolisib— uncovered
ADIPOGENESIS0.204Inavolisib— uncovered
E2F_TARGETS0.198Inavolisib— uncovered
NOTCH_SIGNALING0.186Inavolisib— uncovered
MTORC1_SIGNALING0.183Inavolisib— uncovered
G2M_CHECKPOINT0.159Inavolisib— uncovered
SPERMATOGENESIS0.115Inavolisib— uncovered
GLYCOLYSIS0.086Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.054Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.049Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.035Inavolisib— uncovered
TGF_BETA_SIGNALING0.017Inavolisib— uncovered